Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer
Authors:
- Barbara BurtnessBBBarbara Burtness
- Laurie ThomasLTLaurie Thomas
- Rebecca SipplesRSRebecca Sipples
- Meghan McGurkMMMeghan McGurk
- Saritha SalikootiSSSaritha Salikooti
- Maryanne ChristoforouMCMaryanne Christoforou
- Gayle MirtoGMGayle Mirto
- Ronald SalemRSRonald Salem
- Julieann SosaJSJulieann Sosa
- Robert KlossRKRobert Kloss
- Zia RahmanZRZia Rahman
- Gina ChungGCGina Chung
- 1 July 2007
- journal article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 13 (4) , 257-262
Abstract
Docetaxel and irinotecan have activity in pancreatic cancer. The combination of docetaxel and irinotecan is attractive because of preclinical evidence of synergy between the two drugs. We have previously demonstrated the safety of docetaxel 35 mg/m(2) and irinotecan 50 mg/m(2) given on days 1, 8, 15, and 21 of a 35-day schedule. Patients who had unresectable or metastatic adenocarcinoma of the pancreas, bidimensionally measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and normal bilirubin levels were eligible. Tumor assessment was performed with computed tomography, computed tomographic angiography, or magnetic resonance imaging every 2 cycles. Response was graded according to World Health Organization criteria. We enrolled 37 eligible patients. Principal grade 3/4 toxicities were diarrhea (21%), neutropenia (30%), and hyperglycemia (30%). There were 3 patients with febrile neutropenia and no toxic deaths. There were 4 early deaths. Among 36 evaluable patients, 9 (24%) attained a partial response and 1 (3%) attained a complete response for an objective response rate of 27%. One patient enrolled because she had been deemed to have unresectable disease but then underwent resection with negative margins after attaining a confirmed partial response. Median survival for all eligible patients is 9.4 months (range 0-68+ months) with minimum follow-up for surviving patients of 23.4 months. One-year survival is 43%. The patient who attained a complete response is alive with recurrent disease at 68 months. The docetaxel/irinotecan combination given on a weekly schedule is an active treatment for advanced pancreatic cancer.Keywords
This publication has 26 references indexed in Scilit:
- Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2005
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Prognosis of Cancers Associated with Venous ThromboembolismNew England Journal of Medicine, 2000
- A phase II studyEuropean Journal of Cancer, 2000
- In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell linesCancer Chemotherapy and Pharmacology, 1998
- Effect of CPT-11 in combination with other anticancer agents in lung cancer cellsAnti-Cancer Drugs, 1997
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958